The clinical, biochemical and genetic data generated in the PoCCardio clinical trial are used to develop a computational AI-based tool for predicting the risk of a heart attack and therapy response in patients.

13 out of 29 study centres in Austria, Germany and Poland have begun recruiting participants for the trial of the PoCCardio point-of-care solution.

PoCCardio welcomes the Bioinformatics Department at CING - The Cyprus Institute of Neurology and Genetics

Mobile device to replace laboratory tests